Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Absence of bone sialoprotein (BSP) impairs primary bone formation and resorption: the marrow ablation model under PTH challenge.

Wade-Gueye NM, Boudiffa M, Vanden-Bossche A, Laroche N, Aubin JE, Vico L, Lafage-Proust MH, Malaval L.

Bone. 2012 May;50(5):1064-73.

PMID:
22586700
2.

Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.

Zhu Q, Zhou X, Zhu M, Wang Q, Goltzman D, Karaplis A, Miao D.

J Bone Miner Res. 2013 Sep;28(9):1898-911. doi: 10.1002/jbmr.2000.

3.

Bone Shaft Revascularization After Marrow Ablation Is Dramatically Accelerated in BSP-/- Mice, Along With Faster Hematopoietic Recolonization.

Bouleftour W, Granito RN, Vanden-Bossche A, Sabido O, Roche B, Thomas M, Linossier MT, Aubin JE, Lafage-Proust MH, Vico L, Malaval L.

J Cell Physiol. 2017 Sep;232(9):2528-2537. doi: 10.1002/jcp.25630. Epub 2017 Apr 10.

PMID:
27704558
4.

Skeletal development of mice lacking bone sialoprotein (BSP)--impairment of long bone growth and progressive establishment of high trabecular bone mass.

Bouleftour W, Boudiffa M, Wade-Gueye NM, Bouët G, Cardelli M, Laroche N, Vanden-Bossche A, Thomas M, Bonnelye E, Aubin JE, Vico L, Lafage-Proust MH, Malaval L.

PLoS One. 2014 May 9;9(5):e95144. doi: 10.1371/journal.pone.0095144. eCollection 2014.

5.

Blocking the expression of both bone sialoprotein (BSP) and osteopontin (OPN) impairs the anabolic action of PTH in mouse calvaria bone.

Bouleftour W, Bouet G, Granito RN, Thomas M, Linossier MT, Vanden-Bossche A, Aubin JE, Lafage-Proust MH, Vico L, Malaval L.

J Cell Physiol. 2015 Mar;230(3):568-77. doi: 10.1002/jcp.24772.

PMID:
25160656
6.

Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment.

Wade-Gueye NM, Boudiffa M, Laroche N, Vanden-Bossche A, Fournier C, Aubin JE, Vico L, Lafage-Proust MH, Malaval L.

Endocrinology. 2010 Nov;151(11):5103-13. doi: 10.1210/en.2010-0091. Epub 2010 Sep 15.

PMID:
20844009
7.

Bone sialoprotein deficiency impairs osteoclastogenesis and mineral resorption in vitro.

Boudiffa M, Wade-Gueye NM, Guignandon A, Vanden-Bossche A, Sabido O, Aubin JE, Jurdic P, Vico L, Lafage-Proust MH, Malaval L.

J Bone Miner Res. 2010 Dec;25(12):2669-79. doi: 10.1002/jbmr.245. Erratum in: J Bone Miner Res. 2011 Feb;26(2):439.

8.

Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.

Valverde P, Zhang J, Fix A, Zhu J, Ma W, Tu Q, Chen J.

J Bone Miner Res. 2008 Nov;23(11):1775-88. doi: 10.1359/jbmr.080605.

9.

Parathyroid hormone regulates the distribution and osteoclastogenic potential of hematopoietic progenitors in the bone marrow.

Jacome-Galarza CE, Lee SK, Lorenzo JA, Aguila HL.

J Bone Miner Res. 2011 Jun;26(6):1207-16. doi: 10.1002/jbmr.324.

10.

Osteoclast-specific Dicer gene deficiency suppresses osteoclastic bone resorption.

Mizoguchi F, Izu Y, Hayata T, Hemmi H, Nakashima K, Nakamura T, Kato S, Miyasaka N, Ezura Y, Noda M.

J Cell Biochem. 2010 Apr 1;109(5):866-75. doi: 10.1002/jcb.22228.

PMID:
20039311
11.

Mineralization defects in cementum and craniofacial bone from loss of bone sialoprotein.

Foster BL, Ao M, Willoughby C, Soenjaya Y, Holm E, Lukashova L, Tran AB, Wimer HF, Zerfas PM, Nociti FH Jr, Kantovitz KR, Quan BD, Sone ED, Goldberg HA, Somerman MJ.

Bone. 2015 Sep;78:150-64. doi: 10.1016/j.bone.2015.05.007. Epub 2015 May 9.

12.

E-selectin ligand 1 regulates bone remodeling by limiting bioactive TGF-β in the bone microenvironment.

Yang T, Grafe I, Bae Y, Chen S, Chen Y, Bertin TK, Jiang MM, Ambrose CG, Lee B.

Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7336-41. doi: 10.1073/pnas.1219748110. Epub 2013 Apr 15.

13.

EphrinB2/EphB4 inhibition in the osteoblast lineage modifies the anabolic response to parathyroid hormone.

Takyar FM, Tonna S, Ho PW, Crimeen-Irwin B, Baker EK, Martin TJ, Sims NA.

J Bone Miner Res. 2013 Apr;28(4):912-25. doi: 10.1002/jbmr.1820.

14.

Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.

Machado do Reis L, Kessler CB, Adams DJ, Lorenzo J, Jorgetti V, Delany AM.

Bone. 2008 Aug;43(2):264-73. doi: 10.1016/j.bone.2008.03.024. Epub 2008 Apr 13.

16.

Expression of osteoclastogenic factor transcripts in osteoblast-like UMR-106 cells after exposure to FGF-23 or FGF-23 combined with parathyroid hormone.

Teerapornpuntakit J, Wongdee K, Krishnamra N, Charoenphandhu N.

Cell Biol Int. 2016 Mar;40(3):329-40. doi: 10.1002/cbin.10573. Epub 2016 Jan 12.

PMID:
26694880
17.

Novel bioactivity of phosvitin in connective tissue and bone organogenesis revealed by live calvarial bone organ culture models.

Liu J, Czernick D, Lin SC, Alasmari A, Serge D, Salih E.

Dev Biol. 2013 Sep 1;381(1):256-75. doi: 10.1016/j.ydbio.2013.06.005. Epub 2013 Jun 18.

18.

Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.

Ma YL, Cain RL, Halladay DL, Yang X, Zeng Q, Miles RR, Chandrasekhar S, Martin TJ, Onyia JE.

Endocrinology. 2001 Sep;142(9):4047-54.

PMID:
11517184
19.

Transgenic overexpression of tartrate-resistant acid phosphatase is associated with induction of osteoblast gene expression and increased cortical bone mineral content and density.

Gradin P, Hollberg K, Cassady AI, Lång P, Andersson G.

Cells Tissues Organs. 2012;196(1):68-81. doi: 10.1159/000330806. Epub 2012 Jan 12.

PMID:
22248481
20.

Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.

Ihara H, Denhardt DT, Furuya K, Yamashita T, Muguruma Y, Tsuji K, Hruska KA, Higashio K, Enomoto S, Nifuji A, Rittling SR, Noda M.

J Biol Chem. 2001 Apr 20;276(16):13065-71. Epub 2001 Jan 22.

Supplemental Content

Support Center